查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1993826

生物製药CDMO市场：全球产业分析、市场规模、市场占有率及预测（依生物製药产品类型、生产技术、服务类型、企业规模、最终用户、国家及地区划分，2025年至2032年）

Biologics CDMO Market, By Biologics Type, By Production Technology, By Service Type, By Scale of Operation, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 347 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年生物製药 CDMO 市值为 219.7598 亿美元，预计从 2025 年到 2032 年将以 9.20% 的复合年增长率成长。

生物製剂CDMO（合约研发生产机构）市场指的是为生物製药公司提供生物製剂研发、生产和商业化支援的专业服务供应商。这些机构提供端到端的解决方案，包括细胞株开发、製程开发、分析测试和大规模生产。生物製剂CDMO利用先进的生物製程技术、自动化和品管系统，确保符合法规要求、产品一致性和生产效率。这些优势有助于製药公司缩短产品上市时间、降低营运复杂性并优化生产成本。透过提供扩充性且柔软性的生物製药生产解决方案，CDMO支援创新治疗方法的发展，并使更多患者能够获得安全有效的生物製药治疗。

生物製药CDMO市场－市场动态

生物製药需求不断成长

生物製药需求的不断增长指的是各个治疗领域对创新、复杂且高价值的生物製药疗法的需求日益增加。这促使生物製药公司将研发和生产外包给合约研发生产力机构（CDMO）。这一趋势使CDMO能够扩大产能、简化运营，并提供端到端的解决方案以满足不断增长的市场需求。就生物製剂CDMO而言，此因素有助于加速製程开发、实现可扩展的生产以及符合监管要求的高品质生产。因此，CDMO可以缩短产品上市时间、提高产品一致性并优化资源利用。不断增长的需求也推动了对先进生物製程技术、自动化和分析能力的投资，使CDMO能够有效率地管理大规模的生产规模和更复杂的生物製剂。例如，截至2025年9月，印度製药和生技产业的市场规模在2025财年约为4.71,075兆卢比（550亿美元），预计到2030年，整个产业的市场规模将达到1.1,345兆卢比（1,300亿美元）。这反映了强劲的市场成长和全球竞争力。过去十年，在政府支持力度加大、出口成长以及高素质劳动力的推动下，印度生物技术产业（包括生物製药和生物相似药）的规模从2015年的8.565万亿卢比（100亿美元）增长到2024年的86.9348万亿卢比（1015亿美元）。这些趋势表明，在有利的政策和不断提升的生产能力的支持下，印度在生物製剂和生物相似药领域的地位日益巩固。

生物製剂CDMO市场－市场区隔分析：

全球生物製剂 CDMO 市场按生物製剂类型、生产技术、服务类型、业务规模、最终用户和地区进行细分。

根据生物製药的类型，市场可细分为多个类别：单株抗体、重组蛋白、疫苗、基因疗法和细胞疗法。单株抗体因其广泛的治疗应用以及在肿瘤、自体免疫疾病和感染疾病治疗领域的高需求，占据了市场的大部分份额。对单株抗体的高需求表明，人们越来越需要靶向性强、疗效显着的生物製药疗法来应对复杂的疾病。生物製剂合约研发生产机构（CDMO）透过优化製程开发、大规模生产和严格的品管来满足这一需求，从而确保单株抗体的及时供应，并确保患者能够高效地获得关键的生物疗法。例如，根据美国政府预测，截至2024年，单株抗体（mAb）将成为全球成长最快的治疗药物类别之一，2023年全球mAb市场规模约2,050亿美元，预计到2030年将超过3,000亿美元。这反映了单株抗体在肿瘤学、自体免疫疾病和感染疾病领域的广泛临床应用。到2023年，已有超过120种单株抗体疗法获得核准，并透过在低收入和中等收入国家的推广应用，扩大了全球可及性。这些趋势表明，对生物目标疗法日益增长的需求正在推动对生产能力、监管支持和加强全球合作的投资，以提高治疗的可及性和改善医疗效果。

根据生产技术，市场可分为三大类：哺乳动物细胞培养、微生物发酵和植物来源表现系统。哺乳动物细胞培养技术占据了市场的大部分份额，因为它能够生产具有适当转译后修饰的复杂、高品质生技药品。高效和多功能的生产技术是指能够在保持结构和功能完整性的前提下，可靠地大量生产生技药品。在基于哺乳动物细胞培养的生产中，这种高效性和多功能性使生技药品合约研发生产机构（CDMO）能够满足日益增长的全球需求，优化产量，并以高精度和高重复性生产单株抗体和重组蛋白等复杂分子。例如，根据GFI欧洲组织的报告，德国植物来源食品零售市场（欧洲最大的植物来源食品市场）的总规模在2024年约为16.8亿欧元，较2023年增长1.5%，较2022年增长6.8%。此外，2024年销量达9.71亿件，较2023年成长6.1%，较上年成长11.9%。同时，销售量增加至5.12亿公斤，较2023年成长7.1%，较2022年成长13.5%，显示德国零售业对植物来源食品的需求持续强劲。这些数据凸显了消费者对肉类、乳製品和饮料、优格和奶油等植物来源食品的市场渗透率正在不断扩大。

生物製剂CDMO市场－区域洞察

生物製剂CDMO市场受生物製药生产能力、法规结构和技术应用差异的影响，呈现明显的区域性差异。北美市场发展稳健，这得益于其完善的生物製剂生产基础设施、强劲的研发投入以及对合约开发和生产服务（尤其是美国和加拿大）的旺盛需求。欧洲市场持续成长，这主要得益于生物製剂生产投资的增加、有利的监管政策以及先进生产技术的应用。亚太地区市场快速扩张，其动力来自生物製药产量的成长、医疗保健支出的增加、庞大的病患群体以及中国、印度、日本和韩国等国政府为促进生物製药发展而采取的各项措施。相较之下，拉丁美洲和中东及非洲市场则在生物製造能力的提升、监管环境的现代化以及生物製药开发和生产服务外包业务的增加等方面，正逐步增强其市场份额。

美国生物製药CDMO市场—各国概况

美国生物製药CDMO市场正经历稳定成长，这主要得益于强大的生物製药生态系统以及生物製药研发和生产外包的日益普及。生物製药公司越来越多地与CDMO合作，以缩短药物研发週期、提升生产能力并确保符合监管要求。领先CDMO的积极进入，以及支持生物製药创新和生产的政策，持续推动市场扩张。此外，对成本效益高的扩充性和高品质生物製药生产的日益重视，进一步加速了CDMO在各个治疗领域和商业开发平臺的应用。例如，根据DCAT 2024年1月发布的报告，预计到2028年，整个CDMO市场将以7.29%的年均复合增长率增长，其中生物製药CDMO行业预计将从2023年的151亿美元增长到2028年底的270亿美元，复合年增长率（CAGR）为12.3%。这是由生物技术公司产品线的扩张以及对复杂生物製药和细胞及基因治疗服务日益增长的需求所驱动的，凸显了持续的投资和外包趋势如何塑造生物和製药行业的外包环境。

目录

第一章：生物製药CDMO市场概述

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：生物製药CDMO的关键市场趋势

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 未来市场趋势

第四章：生物製药CDMO产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长前景展望图
  • 管理体制分析

第五章：生物製药CDMO市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：生物製药CDMO市场现状

  • 2024年生物製药CDMO市占分析
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章：生物製药CDMO市场：依生物製药类型划分

  • 概述
    • 细分市场占有率分析：依生物製药类型划分
    • 细胞和基因治疗
    • 单株抗体
    • 重组蛋白
    • 疫苗

第八章：生物製药CDMO市场：依生产技术划分

  • 概述
    • 细分市场占有率分析：依製造技术划分
    • 植物来源的表达系统
    • 哺乳动物细胞培养
    • 微生物发酵

第九章：生物製药CDMO市场：依服务类型划分

  • 概述
    • 基于细分市场的市场占有率分析：按服务类型
    • 分析与发展
    • 临床生产
    • 商业生产
    • 製程开发
    • 品管测试

第十章：生物製药CDMO市场：依企业规模划分

  • 概述
    • 细分市场占有率分析：依企业规模划分
    • 大规模
    • 中号
    • 小规模小规模

第十一章：生物製药CDMO市场：以最终用户划分

  • 概述
    • 基于细分市场的市场份额分析：按最终用户划分
    • 学术机构
    • 製药公司
    • 生技公司

第十二章：生物製药CDMO市场：依地区划分

  • 介绍
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 主要製造商：欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 概述
    • 主要製造商：亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他亚太国家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他拉丁美洲国家
  • 中东和非洲
    • 概述
    • 主要生产商：中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他中东和非洲国家

第十三章：主要供应商分析：生物製药CDMO产业

  • 竞争基准
    • 竞争对手仪錶板
    • 竞争定位
  • 公司简介
    • AbbVie Inc.
    • AGC Biologics
    • Avid Bioservices
    • Binex Co. Ltd.
    • Bioreliance
    • Bora Pharmaceuticals Co. Ltd.
    • Catalent
    • Eurofins Scientific
    • Evonik Industries AG
    • Fujifilm Diosynth Biotechnologies
    • KBI Biopharma
    • Lonza
    • Recipharm
    • Rentschler Biopharma SE
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • WuXi AppTec
    • 3P Biopharmaceuticals SLU
    • Others

第十四章：AnalystView 的全景视图

简介目录
Product Code: ANV6177

Biologics CDMO Market size was valued at US$21,975.98 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.

The Biologics CDMO (Contract Development and Manufacturing Organization) Market refers to specialized service providers that assist biopharmaceutical companies in the development, manufacturing, and commercialization of biologic drugs. These organizations offer end-to-end solutions, including cell line development, process development, analytical testing, and large-scale manufacturing. Biologics CDMOs leverage advanced bioprocessing technologies, automation, and quality management systems to ensure regulatory compliance, product consistency, and efficiency. They help accelerate time-to-market, reduce operational complexity, and optimize production costs for pharmaceutical developers. By providing scalable and flexible biologics manufacturing solutions, CDMOs support the growth of innovative therapies, enabling broader access to safe and effective biologic treatments.

Biologics CDMO Market- Market Dynamics

Increasing Demand for Biologics

Increasing demand for biologics refers to the growing need for innovative, complex, and high-value biologic therapies across therapeutic areas, which drives biopharmaceutical companies to outsource development and manufacturing to Contract Development and Manufacturing Organizations (CDMOs). This trend enables CDMOs to expand production capacity, streamline operations, and offer end-to-end solutions that meet rising market demand. In the Biologics CDMO context, this driver supports accelerated process development, scalable manufacturing, and high-quality regulatory-compliant production. Consequently, CDMOs are able to reduce time-to-market, improve product consistency, and optimize resource utilization. Increasing demand also drives investment in advanced bioprocessing technologies, automation, and analytical capabilities, allowing CDMOs to manage larger production volumes and more complex biologics efficiently. For instance, in September 2025, the Indian pharmaceutical and biotech sector was valued at approximately Rs. 4,71,075 crore (US$ 55 billion) in FY25, and the broader industry is forecast to reach Rs. 1,13,450 crore (US$ 130 billion) by 2030, reflecting strong market growth and global competitiveness. Over the past decade, the Indian biotech industry, encompassing biologics and biosimilars, expanded from Rs. 85,650 crore (US$ 10 billion) in 2015 to Rs. 869,348 crore (US$ 101.5 billion) in 2024, driven by increasing government support, exports, and a skilled workforce. These developments illustrate the nation's strengthening position in the biologics and biosimilars space, supported by favorable policies and advancing manufacturing capabilities.

Biologics CDMO Market- Segmentation Analysis:

The Global Biologics CDMO Market is segmented on the basis of Biologics Type, Production Technology, Service Type, Scale of Operation, End User, and Region.

The market is divided into several categories based on biologic type: monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and cell therapies. The Monoclonal Antibodies segment accounts for a significant portion of the market due to its wide therapeutic applications and high demand across oncology, autoimmune, and infectious disease treatments. High demand for monoclonal antibodies refers to the increasing need for targeted and effective biologic therapies that address complex diseases. In Biologics CDMOs, addressing this demand is achieved through optimized process development, high-capacity production, and stringent quality control, enabling timely availability of monoclonal antibodies and ensuring patients have access to critical biologic therapies efficiently. For instance, in 2024, according to the US Government, monoclonal antibodies (mAbs) have become one of the fastest-growing classes of therapeutic agents globally, with the global mAb market valued at approximately USD 205 billion in 2023 and projected to reach over USD 300 billion by 2030, reflecting widespread clinical adoption across oncology, autoimmune diseases, and infectious diseases. By 2023, over 120 monoclonal antibody therapies were approved, with expansion into low- and middle-income countries boosting global access. These trends highlight that growing demand for targeted biologic therapies is driving increased investment in manufacturing capacity, regulatory support, and global collaboration to enhance accessibility and health outcomes.

The market is divided into three categories based on production technology: mammalian cell culture, microbial fermentation, and plant-based expression systems. The Mammalian Cell Culture segment accounts for a significant portion of the market due to its ability to produce complex and high-quality biologics with proper post-translational modifications. High efficiency and versatility in production refer to the capability of a technology to reliably generate large quantities of biologics while maintaining structural and functional integrity. In mammalian cell culture-based production, this efficiency and versatility allow biologics CDMOs to meet growing global demand, optimize yields, and produce complex molecules such as monoclonal antibodies and recombinant proteins with high precision and reproducibility. For instance, in 2024, according to the GFI Europe Organization report, the total plant-based food retail market in Germany, Europe's largest plant-based market, was valued at approximately €1.68 billion, marking a 1.5% increase over 2023 and a 6.8% rise compared with 2022. Additionally, unit sales reached 971 million in 2024, up 6.1% from 2023 and 11.9% relative, while sales volume climbed to 512 million kg, an increase of 7.1% versus 2023 and 13.5% versus 2022, demonstrating a continued rise in underlying demand for plant-based foods in the German retail sector. These figures highlight growing consumer engagement with plant-based options across meat, milk and drinks, yogurt, and cream categories, reflecting expanding market adoption driven by affordability and changing dietary preferences.

Biologics CDMO Market- Geographical Insights

The Biologics CDMO Market exhibits clear regional variation, shaped by differences in biopharmaceutical manufacturing capacity, regulatory frameworks, and technology adoption. North America shows steady adoption, supported by well-established biologics manufacturing infrastructure, robust R&D investment, and high demand for contract development and manufacturing services, particularly in the U.S. and Canada. Europe demonstrates consistent growth, driven by increasing investment in biologics production, supportive regulatory policies, and adoption of advanced manufacturing technologies. Asia Pacific is expanding rapidly, fueled by growing biopharmaceutical production, rising healthcare expenditure, large patient populations, and government initiatives promoting biologics development in countries such as China, India, Japan, and South Korea. In contrast, Latin America, the Middle East, and Africa are gradually strengthening their market presence, supported by improving biomanufacturing capabilities, regulatory modernization, and growing outsourcing of biologics development and production services.

United States Biologics CDMO Market - Country Insights

The United States Biologics CDMO market is experiencing steady growth, driven by a robust biopharmaceutical ecosystem and increasing outsourcing of biologics development and manufacturing. Biopharmaceutical companies are increasingly partnering with CDMOs to accelerate drug development timelines, enhance manufacturing capacity, and ensure regulatory compliance. Strong participation from leading contract development and manufacturing organizations, along with supportive policies that promote biopharmaceutical innovation and production, continues to encourage market expansion. Additionally, growing emphasis on cost-effective scalability and high-quality biologics production is further accelerating adoption across therapeutic and commercial development pipelines. For instance, in January 2024, according to the DCAT organization , the overall CDMO market is expected to grow at an annualized rate of 7.29% through 2028, with the biologics CDMO sector projected to expand from $15.1 billion in 2023 to $27.0 billion by the end of 2028 at a 12.3% CAGR, driven by expanding biotech pipelines and growing demand for complex biologics and cell- and gene-therapy services, underscoring how sustained investment and outsourcing trends are shaping the bio/pharma outsourcing landscape.

Biologics CDMO Market- Competitive Landscape:

The Biologics CDMO market is moderately concentrated, with several leading contract development and manufacturing organizations driving competition. Key players include 3P Biopharmaceuticals S.L.U., AGC Biologics, Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd., Evonik Industries AG, Rentschler Biopharma SE, Lonza, Samsung Biologics, WuXi AppTec, Catalent, Fujifilm Diosynth Biotechnologies, Recipharm, KBI Biopharma, Avid Bioservices, AbbVie Inc., Bioreliance, Thermo Fisher Scientific Inc., and Eurofins Scientific. These companies compete by providing comprehensive biologics development and manufacturing services, including cell line development, process development, clinical and commercial manufacturing, and quality control. For example, in 2024, Lonza expanded its biologics manufacturing capabilities by integrating continuous bioprocessing technologies, enabling higher production efficiency and reduced timelines for complex therapies. The market is driven by increasing demand for innovative biologic therapies, including monoclonal antibodies, recombinant proteins, and gene and cell therapies. Additionally, CDMOs are broadening their service offerings to include advanced analytical testing, regulatory support, and scalable manufacturing solutions to meet the evolving needs of biopharmaceutical companies and accelerate global access to high-quality therapies.

Recent Developments:

In July 2024, Bora Pharmaceuticals Co. Ltd announced a strategic collaboration with a leading biopharmaceutical innovator to expand its biologics CDMO capabilities and accelerate process development for complex biologic therapies. This initiative demonstrates Bora Pharmaceuticals' commitment to leveraging cutting-edge technologies to enhance manufacturing efficiency and support faster drug development timelines, potentially setting a new benchmark in the contract development and manufacturing space. The partnership is set to utilize advanced bioprocessing platforms and integrated analytics, positioning Bora Pharmaceuticals as a leader in high-performance biologics solutions.

In January 2025, Evonik Industries AG unveiled a major expansion of its biologics CDMO services through a collaboration with global biopharma partners to implement next-generation cell culture and purification technologies. This effort highlights Evonik's focus on deploying innovative manufacturing solutions to improve product quality, reduce production timelines, and meet growing demand for complex biologic therapies. The initiative reinforces Evonik's role as a key provider of advanced biologics manufacturing services and strengthens its competitive position in the evolving CDMO market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • AGC Biologics
  • Avid Bioservices
  • Binex Co. Ltd.
  • Bioreliance
  • Bora Pharmaceuticals Co. Ltd.
  • Catalent
  • Eurofins Scientific
  • Evonik Industries AG
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • Lonza
  • Recipharm
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
  • 3P Biopharmaceuticals S.L.U.
  • Others

GLOBALBIOLOGICS CDMO MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Cell and Gene Therapies
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines

GLOBAL BIOLOGICS CDMO MARKET, BY PRODUCTION TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Plant-based Expression Systems
  • Mammalian Cell Culture
  • Microbial Fermentation

GLOBAL BIOLOGICS CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Analytical Development
  • Clinical Manufacturing
  • Commercial Manufacturing
  • Process Development
  • Quality Control Testing

GLOBAL BIOLOGICS CDMO MARKET, BY SCALE OF OPERATION- MARKET ANALYSIS, 2019 - 2032

  • Large Scale
  • Medium Scale
  • Small Scale

GLOBAL BIOLOGICS CDMO MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Academic Institutions
  • Pharmaceutical Companies
  • Biotechnology Companies

GLOBAL BIOLOGICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biologics CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biologics CDMO Market Snippet by Biologics Type
    • 2.1.2. Biologics CDMO Market Snippet by Production Technology
    • 2.1.3. Biologics CDMO Market Snippet by Service Type
    • 2.1.4. Biologics CDMO Market Snippet by Scale of Operation
    • 2.1.5. Biologics CDMO Market Snippet by End User
    • 2.1.6. Biologics CDMO Market Snippet by Country
    • 2.1.7. Biologics CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Biologics CDMO Key Market Trends

  • 3.1. Biologics CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biologics CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biologics CDMO Market Opportunities
  • 3.4. Biologics CDMO Market Future Trends

4. Biologics CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biologics CDMO Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biologics CDMO Market Landscape

  • 6.1. Biologics CDMO Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biologics CDMO Market - By Biologics Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Biologics Type, 2024&2032 (%)
    • 7.1.2. Cell and Gene Therapies
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Recombinant Proteins
    • 7.1.5. Vaccines

8. Biologics CDMO Market - By Production Technology

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Production Technology, 2024&2032 (%)
    • 8.1.2. Plant-based Expression Systems
    • 8.1.3. Mammalian Cell Culture
    • 8.1.4. Microbial Fermentation

9. Biologics CDMO Market - By Service Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Service Type, 2024&2032 (%)
    • 9.1.2. Analytical Development
    • 9.1.3. Clinical Manufacturing
    • 9.1.4. Commercial Manufacturing
    • 9.1.5. Process Development
    • 9.1.6. Quality Control Testing

10. Biologics CDMO Market - By Scale of Operation

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Scale of Operation, 2024&2032 (%)
    • 10.1.2. Large Scale
    • 10.1.3. Medium Scale
    • 10.1.4. Small Scale

11. Biologics CDMO Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
    • 11.1.2. Academic Institutions
    • 11.1.3. Pharmaceutical Companies
    • 11.1.4. Biotechnology Companies

12. Biologics CDMO Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Biologics CDMO Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Biologics CDMO Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Biologics CDMO Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. PhilippinesMarket Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Biologics CDMO Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Biologics CDMO Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Production Technology, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Scale of Operation, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Biologics CDMO Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. AbbVie Inc.
    • 13.2.2. AGC Biologics
    • 13.2.3. Avid Bioservices
    • 13.2.4. Binex Co. Ltd.
    • 13.2.5. Bioreliance
    • 13.2.6. Bora Pharmaceuticals Co. Ltd.
    • 13.2.7. Catalent
    • 13.2.8. Eurofins Scientific
    • 13.2.9. Evonik Industries AG
    • 13.2.10. Fujifilm Diosynth Biotechnologies
    • 13.2.11. KBI Biopharma
    • 13.2.12. Lonza
    • 13.2.13. Recipharm
    • 13.2.14. Rentschler Biopharma SE
    • 13.2.15. Samsung Biologics
    • 13.2.16. Thermo Fisher Scientific Inc.
    • 13.2.17. WuXi AppTec
    • 13.2.18. 3P Biopharmaceuticals S.L.U.
    • 13.2.19. Others

14. 360 Degree AnalystView

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us